Izotropic's "Izotropic Africa" Enters Partnership Discussions with the Mohammed VI Foundation for Science & Health
Sacramento, California--(Newsfile Corp. - February 25, 2026) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic", or the "Company"), a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses, and treatment of breast cancers, announces that, further to its February 18t
2026-02-25 8:00 AM EST | Izotropic Corporation
Cardiol Therapeutics to Present at TD Cowen 46th Annual Health Care Conference
Toronto, Ontario--(Newsfile Corp. - February 25, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease, is pleased to announce that it will participate at the upcoming TD Cowen 46th Annual Health Care Conference in Boston, MA. Members of management will present on March 4, 2026, at 10:30 a.m. EST.
Biotechnology, Cannabis, Health, Cannabis Manufacturer
2026-02-25 7:27 AM EST | Cardiol Therapeutics Inc.
Scryb Reports Positive Q1 2026: Cash Increased 50%, Liabilities Down 27%, Remains Largest Shareholder of Cybeats
Toronto, Ontario--(Newsfile Corp. - February 25, 2026) - Scryb Inc. (CSE: SCYB) ("Scryb" or the "Company") announces that it has filed its audited consolidated financial statements and Management's Discussion and Analysis for the fiscal quarter ended December 31, 2025 ("Q1 2026"). The filings are available on SEDAR+. Q1 2026 Highlights Cash position improved by 50% to $1.2 million (from $0.8 million at September 30, 2025), with working capital rising 6
Biotechnology, Healthcare and Hospitals, Health
2026-02-25 7:01 AM EST | Scryb Inc.
PreveCeutical Announces Canadian Patent Office Allowance of Innovative Pain Therapy Technology
Vancouver, British Columbia--(Newsfile Corp. - February 25, 2026) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H0) (the "Company" or "PreveCeutical") is pleased to announce that the Canadian Patent Office has allowed Canadian Patent Application No. 3127020, titled "A Cyclic Peptide", which relates to the Company's pain therapy program. This allowance represents a significant milestone in the protection of PreveCeutical's proprietary technologies aime
Biotechnology, Pharmaceuticals, Health
2026-02-25 3:00 AM EST | PreveCeutical Medical Inc.
Envoy Medical Regains Compliance with Nasdaq Listing Requirement
White Bear Lake, Minnesota--(Newsfile Corp. - February 24, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced that it has received written notification from The Nasdaq Stock Market LLC ("Nasdaq") confirming that the Company has evidenced compliance with Nasdaq Listing Rule 5550(b)(2) through the alternatives permitted under Listing Rule 5550(b). As previously disclosed
Biotechnology, Healthcare and Hospitals
2026-02-24 8:00 AM EST | Envoy Medical, Inc.
Envoy Medical Secures Three New Patents Strengthening Competitive Position in the Fully Implanted Hearing Space
White Bear Lake, Minnesota--(Newsfile Corp. - February 23, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced the issuance of three new patents with one in the United States and two in Hong Kong, further expanding its intellectual property and reinforcing its competitive position in the cochlear implant industry. "We believe the future of the cochlear implant industry
Biotechnology, Healthcare and Hospitals
2026-02-23 8:00 AM EST | Envoy Medical, Inc.
Correcting and Replacing: Theralase Bladder Cancer Clinical Data to be Presented at the 2026 European Association of Urology Congress
Toronto, Ontario--(Newsfile Corp. - February 20, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of canc
Technology, Biotechnology, Healthcare and Hospitals, Pharmaceuticals
2026-02-20 7:00 AM EST | Theralase Technologies Inc.
Sernova Biotherapeutics Announces Warrant Amendments
Ontario and Boston, Massachusetts--(Newsfile Corp. - February 20, 2026) - Sernova Biotherapeutics (TSX: SVA) (OTC: SEOVF) (FSE: PSH0) ("the Company"), a leading regenerative medicine company focused on developing its Cell Pouch Bio-hybrid Organ as a functional cure for type 1 diabetes (T1D), today announced that, subject to approval from the TSX, the Company intends to amend some of its outstanding warrants. The Company issued 20,852,100 warrants pursuant to a private
2026-02-20 7:00 AM EST | Sernova Biotherapeutics
Nextleaf Solutions Scales up CPG Brand Growth with an Enhanced National Commercial Platform
Vancouver, British Columbia--(Newsfile Corp. - February 19, 2026) - Nextleaf Solutions Ltd. (CSE: OILS) (OTCQB: OILFF) (FSE: L0MA) ("Nextleaf", "OILS", or the "Company"), a multi-patented life science company and Canadian cannabis processor announced strategic enhancements to its commercial infrastructure, including appointment of Kindred Canada as its national sales agency partner, and the addition of enhanced distribution partners serving Manitoba and Saskatchewan. These initiatives
Biotechnology, Pharmaceuticals, Cannabis, Cannabis Extractor
2026-02-19 9:00 AM EST | Nextleaf Solutions Ltd.
Neural Therapeutics Announces CSE Application to Acquire Full Ownership of Hanf.com, Shareholder Meeting, SIO Agreement Amendment and Concurrent Financing
Toronto, Ontario--(Newsfile Corp. - February 19, 2026) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company") is pleased to announce that it has formally applied to the Canadian Securities Exchange (the "CSE") for approval to acquire the remaining 69.25% interest in CWE European Holdings Inc. ("CWE"), operating as Hanf.com, one of Germany's leading CBD retailers. Ronnie Jaegermann, Chief Executive Officer of CWE, stated: "Hanf.com h
Biotechnology, Pharmaceuticals, Health, Psychedelics
2026-02-19 8:53 AM EST | Neural Therapeutics Inc.
Kiora Pharmaceuticals to Present at Oppenheimer's 36th Annual Healthcare Life Sciences Conference
Encinitas, California--(Newsfile Corp. - February 19, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) today announced that the company will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on Thursday, February 26, 2026, at 3:20 p.m. ET. A live webcast will be available on Kiora's investor relations website, ir.kiorapharma.com, on the
Biotechnology, Pharmaceuticals
2026-02-19 8:30 AM EST | Kiora Pharmaceuticals, Inc.
Envoy Medical Provides Business Update Following Transformative Financing and Positive Progress in Clinical Trial
Financing was led by new investor and top-tier healthcare fund Nantahala Capital and longtime Envoy Medical shareholder, billionaire Glen Taylor Closing of $30 million in gross proceeds in upsized offering, with up to an additional $48 Million upon exercise of milestone warrants, provides potential funding through commercialization Company hosting Fireside Chat with Dr. Theodore
Biotechnology, Healthcare and Hospitals
2026-02-19 8:00 AM EST | Envoy Medical, Inc.
Phio Pharmaceuticals Aligns Leadership Team to Support Next Stage Development of PH-762 and Advancement of PH-894
King of Prussia, Pennsylvania--(Newsfile Corp. - February 19, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-02-19 7:00 AM EST | Phio Pharmaceuticals Corp.
Optimi Health schließt Psilocybin-Export nach Australien zur Behandlung therapieresistenter Depression ab
Vancouver, British Columbia--(Newsfile Corp. - Donnerstag, 19. Februar 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" oder das "Unternehmen"), ein von Health Canada lizenzierter Hersteller von psychedelischen Arzneimitteln in pharmazeutischer Qualität, gab heute den Export seiner nach GMP-Standards hergestellten natürlichen 5-mg-Psilocybin-Kapseln nach Australien bekannt. Diese werden zur Behandlung von Patientinnen und Patiente
Biotechnology, Pharmaceuticals, Health, Psychedelics
2026-02-19 2:00 AM EST | Optimi Health Corp.
Optimi Health Completes Psilocybin Export to Australia for Treatment Resistant Depression
Vancouver, British Columbia--(Newsfile Corp. - February 19, 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Health Canada-licensed manufacturer of pharmaceutical-grade psychedelic drug products, today announced the export of its GMP-manufactured natural 5 mg psilocybin capsules to Australia for the treatment of patients diagnosed with treatment-resistant depression (TRD) under Australia's Authorised Prescriber Scheme.
Biotechnology, Pharmaceuticals, Health, Psychedelics
2026-02-19 2:00 AM EST | Optimi Health Corp.
Resverlogix Closes $2.8 Million Shares-for-Interest Private Placement
Calgary, Alberta--(Newsfile Corp. - February 18, 2026) - Resverlogix Corp. (TSX: RVX) ("Resverlogix") announced today that it has closed a $2.8 million shares-for-interest private placement with an immediate family member (the "Subscriber") of Resverlogix's Chairman and CEO. Under the terms of the shares-for-interest transaction, the Subscriber subscribed for 28,000,000 common shares at CAD$0.10 per share for aggregate proceeds of CAD$2.8 million. After giving effect to the trans
Technology, Biotechnology, Healthcare and Hospitals
2026-02-18 7:00 PM EST | Resverlogix Corp.
Marvel Biosciences Announces Grant of Deferred Share Units
Calgary, Alberta--(Newsfile Corp. - February 18, 2026) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), announces the award of 50,001 deferred share units ("DSUs") to Marvel's three independent directors, in lieu of cash payment for directors' fees. The DSUs will all vest on February 17, 2027. Vested DSUs shall be settled upon the directors' separation from service fr
2026-02-18 4:30 PM EST | Marvel Biosciences Corp.
Marvel Biosciences Secures Funding to Develop Child-Friendly Liquid Formulation for Neurodevelopmental Disorders
Calgary, Alberta--(Newsfile Corp. - February 18, 2026) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), is pleased to announce that it is receiving advisory services and funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to support research and development of a pediatric-friendly liquid formulation of its lead compound, MB-204. The NRC IRAP-supported project will focus on creating a small-volume oral liquid formulation de
2026-02-18 8:00 AM EST | Marvel Biosciences Corp.
Izotropic Signs Letter Agreement for Regional Operations in Africa & the GCC
British Columbia and Sacramento, California--(Newsfile Corp. - February 18, 2026) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic", or the "Company"), a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses, and treatment of breast cancers, announces that it has entered into a Letter Agreement (the "Agreement") with a business group ("BG
2026-02-18 8:00 AM EST | Izotropic Corporation
Telo Genomics Closes First Tranche of Convertible Debentures Financing
Vancouver, British Columbia--(Newsfile Corp. - February 18, 2026) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics"), a leader in the development of diagnostic and prognostic tests for human disease through the analysis of chromosomal telomeres, is pleased to announce that it h
2026-02-18 7:00 AM EST | Telo Genomics Corp.